Home Compare JAZZ
Peer Analysis

Jazz Pharmaceuticals plc — Peer Companies & Stock Comparisons

Jazz Pharmaceuticals plc's functional peer companies ranked by peer score — growth, valuation, profitability and stability compared.

Compare JAZZ with peers
Comparison JAZZ peer score
Jazz Pharmaceuticals plc vs Zimmer Biomet Holdings, Inc.
36 Compare →
Jazz Pharmaceuticals plc vs Becton, Dickinson and Company
54 Compare →
Jazz Pharmaceuticals plc vs Elanco Animal Health Incorporated
42 Compare →
Jazz Pharmaceuticals plc vs TP ICAP Group PLC
45 Compare →
Jazz Pharmaceuticals plc vs Assurant, Inc.
45 Compare →
Jazz Pharmaceuticals plc vs Publicis Groupe S.A.
65 Compare →
Jazz Pharmaceuticals plc vs Medtronic plc
51 Compare →
Jazz Pharmaceuticals plc vs Viatris Inc.
40 Compare →
Jazz Pharmaceuticals plc vs Ferrovial SE
45 Compare →
Jazz Pharmaceuticals plc vs W. R. Berkley Corporation
56 Compare →

Full JAZZ analysis in AssetNext

View the complete Jazz Pharmaceuticals plc report including all peer dimensions.

Open in AssetNext →

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.